ISSN: 1178-2595
Journal Home
Journal Guideline
Pharmaceutical Medicine Q2 Unclaimed
Pharmaceutical Medicine is a journal indexed in SJR in Pharmacology and Pharmacology (medical) with an H index of 25. It has a price of 2690 €. It has an SJR impact factor of 0,732 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,732.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2690 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
0,732
SJR Impact factor25
H Index47
Total Docs (Last Year)107
Total Docs (3 years)2050
Total Refs275
Total Cites (3 years)93
Citable Docs (3 years)2.59
Cites/Doc (2 years)43.62
Ref/DocOther journals with similar parameters
Drug Safety - Case Reports Q2
Cancer Biology and Therapy Q2
Journal of Pharmacological Sciences Q2
AIDS Research and Therapy Q2
Pharmacological Reports Q2
Compare this journals
Aims and Scope
Best articles by citations
Harmonised European Standards as a Basis for the Safe Use of Herbal Medicinal Products and Their Marketing Authorisation in European Union Member States
View moreAcquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?
View moreNordic Health Registers as a Source for Value-Based Evidence
View moreOne Programme, Four Stakeholders: An Overview of the Utilisation of Patient-Reported Outcomes in Intervention Development to Meet the Needs of Regulators, Payers, Healthcare Professionals and Patients
View moreSecuritization of a Drug Development Mega-Fund: The Time-Certain Research-Backed Obligation
View moreStrategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond Effectiveness
View moreEvaluation of Pharmacovigilance Practice in Pharmaceutical Companies in Nigeria
View moreMaking the Proper Choices on Education for the Pharmaceutical Industry
View moreMeasuring and Improving Physician Knowledge of Safety Risks Using Traditional and Online Methods in Pharmacovigilance
View moreEarly Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors
View moreAnalysis of Safety-Related Regulatory Actions for New Drugs in Japan by Nature of Identified Risks
View moreStructured Qualitative Benefit-Risk Assessment to Inform Go/No-Go Decisions for Phase III Testing of Pharmaceutical Products
View moreImproving Asthma Outcomes in the Digital Era: A Systematic Review
View morePeriodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective
View moreA Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries
View moreAccreditation Standards for Medical Science Liaison (MSL) Certification Programmes in Japan: A Viewpoint from the Japanese Association of Pharmaceutical Medicine (JAPhMED)
View moreAn Analysis of US Food and Drug Administration Clinical Hold Orders for Drugs and Biologics: A Prospective Study Between 2008 and 2014
View moreA Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016
View moreA Business Intelligence Solution to Pharmacovigilance Signal Tracking and Management: One Mid-Size Pharma's Experience
View moreLiver Test Monitoring: Real-World Compliance for Drugs with Monitoring Requirements at 2-Week Intervals or More Frequently
View moreWill the EU Clinical Trials Regulation Support the Innovative Industry in Bringing New Medicines Faster to Patients?
View morePerspectives on the Emergence of Pharmacovigilance in Public Health Programmes in South Africa
View moreDifferent Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making
View moreVariation in Liver Biochemistries in Patients with Decompensated Cirrhosis: Implications for Assessing Drug-Induced Liver Injury in Clinical Trials
View more
Comments